ClinicalTrials.gg
RecruitingNCT06163963Updated Nov 18, 2026

Sentinel Lymph Node in Early-Stage Endometrium Cancer

An interventional study of Sentinel Lymph Node Mapping With Double Tracer and Double Injection Sites in Early-Stage Endometrium Cancer and charcoal injection to uterus to map sentinel lymph nodes in Sentinel Lymph Node and Endometrial Cancer, sponsored by Istanbul University. Recruiting at 1 site in Turkey (Türkiye). Open to female participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Istanbul University · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Jul 2023, registered Dec 2023).
  • Started Jul 2023; still recruiting 3 years 4 months later.
Updated Nov 18, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
18 Years to 90 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 46 studies in Endometrial Neoplasms with a site in Turkey — 14 open to participants now, 18 under way, 4 of them phase 3. Endometrial Neoplasms · Turkey.

Planned enrollment
14th of 33
100 · median 100
Started
2023
with 5 others
No phase
18 of 46
6 open now
Primary completion
2027-09
later than 9 of 17 live
Registered
29th of 46
by date
Lead sponsor
2 of 46
Istanbul University

Among the 46 studies in Endometrial Neoplasms with a site in Turkey, this one is the 14th largest by planned enrollment of the 33 interventional ones that give a count, is one of 6 that started in 2023, is one of 18 with no phase, reaches primary completion later than 9 of the 17 other live ones, and was the 29th registered.

Endometrial Neoplasms

1,429 studies on the registry are indexed under Endometrial Neoplasms; 470 are open to participants now.

Browse Endometrial Neoplasms studies →

Open to participants now

14 of the 46 studies in Endometrial Neoplasms with a site in Turkey are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 356 Endometrial Neoplasms studies recruiting now, 266 (75%) set no upper age limit and 54 (15%) stop at 75 or younger; 26 take children under 18; 23 take healthy volunteers.

This study: 18 Years to 90 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies in Endometrial Neoplasms with a site in Turkey, or all of them as a file.
02

Study summary

The aim of this prospective study is to investigate whether the detection rate of sentinel lymph node (SLN) with double tracer injected at two different sites may be increased compared to the standard use of a single tracer with single site (cervix) injection in early-stage endometrial cancer.

Read the detailed description

Endometrial cancer is the most common gynecologic cancer. Although 85-90% of women are diagnosed at early stage, about 10-15% are diagnosed at advanced stages. Treatment and prognosis depends on the surgical staging of the apparently early stage disease including the evaluation of lymphatic status of the disease. Detection of positive lymph node upstages the apparently early stage endometrial cancer. However, systematic lymphadenectomy carries immediate and long term risks for patients including bleeding, massive transfusions, prolongation of operation time, serious major vessel and major abdominal organ injury and death. These risks are especially increased in para-aortic lymphadenectomy which is a part of staging procedure in apparently early stage endometrial cancer.

Sentinel lymph node biopsy (SLNB) procedure is the biopsy of one or two lymph node(s) which represents the lymph node basin draining the area of malignancy. This biopsy may potentially eliminate the need systemic pelvic / para-aortic lymphadenectomy which harbours potential complications. Although SLNB became an standard procedure in endometrial cancer, available data on the SLNB in endometrial cancer is variable. The relevant literature suggests that the detection rate of sentinel lymph node using various tracer agents are between %70-98, even with lower for bilateral pelvic detection and para-aortic sentinel lymph node(s). The most commonly used tracer agents are methylene blue, radiolabeled colloid technetium 99 (Tc99), isosulfan blue and fluorescent indocyanine green. Although subserosal, intramyometrial uterine injections and peritumoral injections using hysteroscopy with different tracers and different detection rates have been used, cervical injection with ICG is the most favoured and standard technique with highest pelvic SLN detection rates. However, the para-aortic SLN detection rates are not satisfactory with a single tracer injected into cervix which may be critical especially in high grade endometrioid, serous and clear cell histological types.

So, investigators aimed to investigate whether the sentinel lymph node detection rates may be improved with double tracer injected at two different sites (charcoal carbon black dye injected in subserosa and ICG injected into cervix) compared to standard single tracer injected in early-stage endometrial cancer, especially the para-aortic sentinel lymph nodes. Sterile charcoal carbon black dye is an agent previously used for sentinel lymph node detection in various cancers such as breast cancer.

Technically, 2 mL indocyanine green with sterile water is injected at 3 and 9 o'clocks (each 1 mL) of cervix before the start of laparoscopic operation. Additionally, 2-4 mL of sterile charcoal carbon black dye is carefully injected just beneath the serosal layer at uterine fundus bilaterally avoiding intravascular injection This is done classically during laparoscopy by a spinal needle introduced under optical supervision after all optical and operative instruments are entered. 10-15 minute interval is allowed before the start of harvesting sentinel lymph nodes in pelvic and paraaortic region.

03

Conditions studied

  • Sentinel Lymph Node
  • Endometrial Cancer

Keywords

  • double tracer, endometrial cancer, sentinel lymph node
04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Must have preoperative histologic diagnosis of endometrial carcinoma
  2. Must be in early stage ( stage1 and 2) endometrial carcinoma radiologically and clinically
  3. Must have written

Exclusion criteria

Exclusion Criteria:

  1. Possible allergic reaction to commonly used drugs
  2. Medical or surgical for comphrensive staging
  3. Preoperative or intraoperative findings of advanced endometrial cancer
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Sentinel Lymph Node Mapping With Double Tracer in Endometrium Cancer (Single Arm)

    Sentinel Lymph Node Mapping With Double Tracer and Double Injection Sites in Early-Stage Endometrium Cancer (Single Arm)

    Diagnostic Test: Sentinel Lymph Node Mapping With Double Tracer and Double Injection Sites in Early-Stage Endometrium Cancer · Diagnostic Test: charcoal injection to uterus to map sentinel lymph nodes

Interventions

  • Diagnostic testSentinel Lymph Node Mapping With Double Tracer and Double Injection Sites in Early-Stage Endometrium Cancer

    This is a single arm interventional prospective study. Sentinel lymph node detection rate of the tracer injected in cervix (ICG- indocyanine green) before operation and the second tracer injected in uterine fundal subserosa (sterile charcoal black) at the start of operation are investigated. It is anticipated that additional tracer used in the uterine serosa may overcome the insufficiency (or increase the detection rate) of the standard single tracer injected in cervix for detection rate of sentinel lymph nodes, especially in paraaortic sentinel lymph nodes.

  • Diagnostic testcharcoal injection to uterus to map sentinel lymph nodes

    During surgery for endometrial cancer, charcoal injection to uterus to map sentinel lymph nodes in para aortic area besides the classic ınjection of indocyanine green for pelvic sentinel lymph node mapping.

06

What researchers measure

Primary outcomes

  1. Detection rate of sentinel lymph nodes with double tracer in early stage endometrial carcinoma

    Detection rates of sentinel lymph nodes for both tracers in every pelvic and paraaortic lymph node basin are the primary outcome of the study.Sentinel lymph node detection rates of each region (pelvic, obturator, inframesenteric para-aortic, supra-mesenteric - infrarenal para-aortic), bilaterality/ unilaterality and staining with single or double tracer will be discussed compared to literature data.

    Time frame: From the day of surgery to final pathology report (2 weeks)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Crosbie EJ, Kitson SJ, McAlpine JN, Mukhopadhyay A, Powell ME, Singh N. Endometrial cancer. Lancet. 2022 Apr 9;399(10333):1412-1428. doi: 10.1016/S0140-6736(22)00323-3. PubMed 35397864 ↗
  • Cibula D, Oonk MH, Abu-Rustum NR. Sentinel lymph node biopsy in the management of gynecologic cancer. Curr Opin Obstet Gynecol. 2015 Feb;27(1):66-72. doi: 10.1097/GCO.0000000000000133. PubMed 25502426 ↗
  • Lee YC, Lheureux S, Oza AM. Treatment strategies for endometrial cancer: current practice and perspective. Curr Opin Obstet Gynecol. 2017 Feb;29(1):47-58. doi: 10.1097/GCO.0000000000000338. PubMed 27941361 ↗
  • van den Heerik ASVM, Horeweg N, de Boer SM, Bosse T, Creutzberg CL. Adjuvant therapy for endometrial cancer in the era of molecular classification: radiotherapy, chemoradiation and novel targets for therapy. Int J Gynecol Cancer. 2021 Apr;31(4):594-604. doi: 10.1136/ijgc-2020-001822. Epub 2020 Oct 20. PubMed 33082238 ↗
  • Holloway RW, Abu-Rustum NR, Backes FJ, Boggess JF, Gotlieb WH, Jeffrey Lowery W, Rossi EC, Tanner EJ, Wolsky RJ. Sentinel lymph node mapping and staging in endometrial cancer: A Society of Gynecologic Oncology literature review with consensus recommendations. Gynecol Oncol. 2017 Aug;146(2):405-415. doi: 10.1016/j.ygyno.2017.05.027. Epub 2017 May 28. PubMed 28566221 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2023 (actual). Primary completion is estimated for Sep 2027, 50 months after the start.

Of 194 non-industry interventional studies with no phase under Endometrial Neoplasms, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 76. This study's planned 50 months is above that.

Counting every sponsor, half of 200 studies reached it within 43 months; a quarter within 19 and three quarters within 63.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 18, 2026: primary completion Nov 2025 → Sep 2027 and completion May 2026 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2023
First posted
Dec 11, 2023
StartActual
Jul 1, 2023
Primary completionEst.
Sep 2027was Nov 2025
CompletionEst.
Dec 2027was May 2026
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Nov 2025→Sep 2027
Nov 18, 2026
Study completion
May 2026→Dec 2027
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Primary completion Nov 2025→Sep 2027
    Study completion May 2026→Dec 2027
    + 3 other changes: identifiers, verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06163963
Responsible party
Mustafa Albayrak (Principal Investigator, Istanbul University) — Principal investigator
First posted
Dec 11, 2023
Start date
Jul 1, 2023
Primary completion
Sep 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Nov 18, 2026

Study contacts

Mustafa ALBAYRAK, MD
Contact
mustafaalbayrak@icloud.com
+905326871051
Yagmur MİNARECİ, MD
Contact
yagmurminareci@gmail.com
+905053574361
Samet TOPUZ, PROF. DR.
study director · ISTANBUL UNİVERSİTY MED FAC DEPT. OF OBSTET AND GYNECOL. DIVISION OF GYNECOLOGİC ONCOLOGY

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion